HDAC1 and central nervous system cancer: The HDAC1-related signature was adjusted as an independent risk indicator and eventually validated both internally and externally showing reliable discrimination for glioma prognosis prediction (Supplementary Figure S3; Figures 10D–F; Figures 11A,B).